Elias R, et al. - Researchers analyzed evidence from randomized controlled phase II or III studies comparing efficacy of PD-1 or PD-L1 inhibitors to a non-PD-1/PD-L1 inhibitor in patients with metastatic solid tumors, to ultimately assess the efficacy of Immune Checkpoint Inhibitors (ICIs) based on age, younger vs older than 65 years. Overall, 9 studies were analyzed for overall survival. Five studies investigated nivolumab, 2 investigated pembrolizumab, and 2 investigated atezolizumab. With the use of PD-1/PD-L1 inhibitors, a consistent improvement in survival was noted across age cut-off of 65 years. In adults younger vs ≥ 65 years, comparable efficacy of PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab) inhibitors was demonstrated.